Locations:
Search IconSearch

Study Suggests Feasibility of Alternating-Frequency DBS for Gait Impairment in Parkinson’s

Novel protocol combines gait testing during stimulation with neural signal measurement

22-NEU-2922372-deep-brain-stimulation_650x450

Gait impairment is a crucial unmet need for patients with Parkinson’s disease (PD). While deep brain stimulation (DBS) has been studied to treat it, success has been elusive: use of high frequencies can manage some motor symptoms, but can worsen gait, whereas low frequencies may improve gait, but only transiently.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

A new feasibility study by Cleveland Clinic researchers — ENGAGE-PD (NCT05022147) — suggests that alternating the frequency of DBS may simultaneously control multiple motor symptoms, including gait. Preliminary results of the research, which involves an experimental paradigm that is being tested in a small group of patients, were presented at the XVII World Congress on Parkinson’s Disease and Related Disorders in early May.

“Our hypothesis is that with an alternating-frequency protocol, patients get the benefit of low frequencies for gait and high frequencies for control of other motor symptoms,” says the study’s first author, James Liao, MD, PhD, a movement disorders clinical fellow in Cleveland Clinic’s Center for Neurological Restoration. “We’ve tested six patients so far using a single-day, 12-condition protocol. In the data analyzed to date, the majority of participants had their most stable gait using alternating-frequency DBS, not the traditional high-frequency DBS.”

How the study is being conducted

The protocol for the study, which is ongoing, calls for patients with PD and a Medtronic Percept™ DBS system to perform a five-minute gait test while wearing a wireless headset that displays an augmented-reality obstacle course. Participants perform this gait test under six DBS frequency conditions, in random order:

  • All high frequency
  • All low frequency
  • Long high/short low
  • Long high/long low
  • Short high/short low
  • Short high/long low

The six tests are performed after holding PD medications and then repeated after taking PD medications, for a total of 12 tests. Short duration is 10 seconds, and long duration is 50 seconds. Low frequency is 55 to 60 Hz, and high frequency is 125 to 130 Hz. A two-minute rest tremor assessment is performed after each test condition.

Advertisement

“As patients go through the obstacle course, we use wearable sensors to assess the stability of their gait,” says Dr. Liao. “Then while they are seated between the walking periods, we’re also measuring tremor.”

In addition, neural data are recorded during the tests. EEG signals are captured with an ambulatory EEG system, and subthalamic nucleus local field potentials are recorded with the Percept neurostimulator.

Combining alternating-frequency DBS with neural signal measurement

With the technology involved, gait-related electrophysiology and kinematics can be captured simultaneously and motion/stimulation-related artifact can be mitigated offline. The goals of the study — the first to combine investigation of alternating-frequency DBS with measurement of neural signals — are to identify alternating-frequency strategies that maximize motor benefits and to gain insight into the mechanism of alternating-frequency DBS.

“By analyzing neural data during walking,” Dr. Liao explains, “we hope to figure out how brain activity changes when gait becomes unstable and also learn how DBS modulates brain activity to improve gait.”

All study participants have balance or walking impairment and are able to walk without assistance while off medication. The six patients tested so far on the augmented-reality obstacle course have tolerated the experience, providing support for the feasibility and safety of the approach.

“Our preliminary data show that, in most cases, traditional high-frequency DBS at 125 to 130 Hz isn’t the best DBS condition for gait stability,” notes Dr. Liao. “That’s interesting because it suggests we may be able to improve gait in patients with PD just by adjusting the stimulation frequency.”

Advertisement

Recruitment for the study is ongoing, and the researchers hope to gather additional data in order to draw conclusions about how to best utilize alternating-frequency DBS. “Our ultimate goal is to develop reliable treatments for gait instability and to improve quality of life for our patients without losing the gains they currently enjoy with traditional DBS programming,” says co-investigator Hubert H. Fernandez, MD, Director of Cleveland Clinic’s Center for Neurological Restoration.

Advertisement

Related Articles

two brain scans side by side with a yellow circle on the left scan
March 13, 2026/Neurosciences/Epilepsy

SEEG Linked With More Complete Resection and Greater Seizure Freedom in MOGHE Subtype of Epilepsy

Insights from one of the first studies of invasive monitoring in the rare form of focal cortical dysplasia

histopathology image with pink background and arrow pointing to round cell

New Insights on α-Synuclein Pathology and Clinical Phenotypes in Dementia With Lewy Bodies

The disease’s neuropathologic heterogeneity holds clues to refining diagnosis and prognosis

MRI of the brain against black background

Advanced Neuroimaging and Clinical Perseverance Make Sense of a 68-Year-Old’s Progressive Symptoms

A case study in pairing imaging acumen with subspecialty expertise to yield answers and symptom relief

brain scan with colored dots over a dark gray region
March 3, 2026/Neurosciences/Epilepsy

Decoding the Insula: New Semiological Insights for Localizing Seizure Onset

Guidance from the largest cohort of SEEG-confirmed insular epilepsy patients reported to date

Photo of Dr. Ford
March 2, 2026/Neurosciences/Podcast

Neuroethics Conversations: Guidelines for Care (Podcast)

Ethical guidance provides guardrails so medical advances benefit patients

red blood cells floating in a blood vessel
February 27, 2026/Neurosciences/Cerebrovascular

Factor XIa Inhibition Drives Down Recurrent Stroke Risk Without Rise in Bleeding

OCEANIC-STROKE results represent long-sought advance in secondary stroke prevention

two brightly colored brain scans side by side
February 25, 2026/Neurosciences/Epilepsy

MR Fingerprinting Shows Potential to Reshape FCD Detection and Epileptogenicity Mapping

Two studies from Cleveland Clinic may help advance the technology toward broader clinical use

MRI scan of the side of a human head
February 20, 2026/Neurosciences/Cerebrovascular

Susac Syndrome: Insights on Rare Endotheliopathy From Largest Single-Center Cohort to Date

Distinct MRI signature includes lesions beyond the corpus callosum, features predictive of vision and hearing loss

Ad